Effect of atorvastatin on diabetic rat endothelial cells and retinal lesions

• Published in: Genetics and molecular research 2015-05, Vol.14 (2), p.5462-5467
• Main Authors: Bi, M C, Song, X J, Shi, H, Xue, W X, Xu, C L, Song, E
• Format: Article
• Language: English
• Subjects: Animals; Atorvastatin Calcium - administration & dosage; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - genetics; Diabetes Mellitus, Experimental - pathology; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - genetics; Diabetic Retinopathy - pathology; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Endothelial Cells - pathology; Gene Expression Regulation, Neoplastic - drug effects; Humans; Interleukin-4 - biosynthesis; Rats; Rats, Wistar; Tumor Necrosis Factor Ligand Superfamily Member 15 - biosynthesis; Tumor Necrosis Factor Ligand Superfamily Member 15 - genetics; Tumor Necrosis Factor-alpha - biosynthesis; Tumor Necrosis Factor-alpha - genetics; Vascular Endothelial Growth Factor A - biosynthesis; Vascular Endothelial Growth Factor A - genetics
• ISSN: 1676-5680; 1676-5680
• DOI: 10.4238/2015.May.22.16

We investigated the effect of atorvastatin on vascular endothelial growth inhibitor (VEGI) expression in rats with diabetic retinopathy. Wistar rats were divided into a blank group and diabetic model group, which was further randomly divided into treatment and control groups. Rats in the treatment group received 10 mg/kg atorvastatin daily, while rats in the blank and control groups received normal saline. Rats were randomly euthanized at 3 or 6 months. Immunohistochemical staining was used to determine changes in VEGI and vascular endothelial growth factor, interleukin-4, and tumor necrosis factor α levels in rats with diabetic retinopathy. Survival rate in the treatment group was 84% (63/75) after 6 months, which was significantly higher than that in the control group (P < 0.05); rats in the control group showed the lowest survival rate. Survival in the treatment group was higher than that in the control group but not significant compared with the blank group after 3 months. VEGI, vascular endothelial growth factor, tumor necrosis factor α, and interluekin-4 expression was lower than that in the control group, but higher than the blank group after 3 months. The expression of each factor decreased to the blank group level in the treatment group and was significantly lower than that in the control group after 6 months (P < 0.05). Expression in control and blank groups was similar at 3 and 6 months. Atorvastatin can inhibit VEGI and vascular endothelial growth factor expression to protect rats from diabetic retinopathy.